Evidence, validations and case reports

Evidence for technical decisions.

This page brings together, in one place, the studies, regulatory validations and independent certifications related to the Sterozone/AsepticSure technology, along with the independent scientific literature that underpins the concept of enhanced terminal disinfection. The content is organized for technical reference by infection-control, quality, clinical-engineering, facilities, hospitality and institutional-management professionals.

Each record states its nature, what it specifically supports, its method and conditions, the reported result, its scope and its limitations — without ranking evidence types against each other or presenting them as degrees of regulatory or clinical approval.

Peer-reviewed journal
An article evaluated by independent experts before publication in a scientific journal.
Regulatory (GLP) study
A study conducted under Good Laboratory Practice, following a formal protocol accepted by a regulatory agency.
Case series / conference
A report on a real-world application or a conference abstract — not a controlled clinical trial.
Third-party certification
A compliance assessment carried out by a certification body independent of the manufacturer.
Independent literature
A study that does not test Sterozone/AsepticSure, included only as context and comparator evidence.

This classification is descriptive, not a hierarchy of reliability or a grade of approval — each evidence type has a different role and different limits, detailed in each record below.

Block 1

Direct evidence from the Sterozone/AsepticSure platform

Effectiveness of a novel ozone-based system for the rapid high-level disinfection of health care spaces and surfaces
AJIC 2011 — Zoutman, Shannon & Mandel · 2011
Authorship
Zoutman D, Shannon M, Mandel A.
Relationship to the technology
Direct evidence from the Sterozone/AsepticSure platform
Nature of evidence
Peer-reviewed journal
Access
Subscription-access publication (journal).
What this record supports
The technology's core microbiological efficacy (≥6 log₁₀ reduction) and the synergy between ozone and hydrogen peroxide.
Method / conditions
Test chamber and a 113 m³ room; 80 ppm ozone combined with 1% vaporized hydrogen peroxide; stainless-steel discs inoculated with MRSA, VRE, E. coli, P. aeruginosa, C. difficile and B. subtilis, exposed for 30 to 90 minutes.
Reported result
Under the reference condition (80 ppm ozone + 1% hydrogen peroxide): 6.43 log₁₀ reduction for MRSA (60 min), 6.08 log₁₀ for VRE (60 min), 6.02 log₁₀ for E. coli (60 min), and 5.75 log₁₀ for C. difficile spores (90 min). These figures were checked directly against Table 2 of the original article.
Organisms / scope
MRSA, VRE (vancomycin-resistant Enterococcus), E. coli, P. aeruginosa, C. difficile and B. subtilis (spores) — laboratory assay on stainless-steel discs and cotton gauze.
Limitations
A laboratory result on inoculated surfaces under controlled conditions — not a clinical outcome and not a guarantee of results in any real environment; every application requires its own protocol and validation. Research funded by Medizone International Inc., which also holds the evaluated technology (conflict of interest disclosed by the authors themselves in the article).
Full reference
Zoutman D, Shannon M, Mandel A. "Effectiveness of a novel ozone-based system for the rapid high-level disinfection of health care spaces and surfaces." Am J Infect Control. 2011;39(10):873-879.
Positive impacts of a new ozone and hydrogen peroxide vapour system to disinfect patient rooms during an MRSA outbreak
Belleville 2013 — IPAC Canada 2014 poster · 2013
Authorship
Zoutman D, Shannon M, de la Roche M, Chesterton D, Brown K.
Relationship to the technology
Direct evidence from the Sterozone/AsepticSure platform
Nature of evidence
Case series (conference poster)
Access
Conference material — not published in an indexed journal.
What this record supports
Interruption of a real-world MRSA outbreak on an in-patient unit, with a reduction in viable colony counts after treatment.
Method / conditions
20-bed in-patient unit (Quinte Health Care, Belleville, ON). In June 2013, 6 rooms linked to an MRSA outbreak underwent standard manual terminal cleaning followed by the ozone + hydrogen peroxide vapour system (50 ppm vaporized hydrogen peroxide + 80 ppm ozone, 60-minute cycle per room). Ten surfaces per room were cultured with contact plates before and after each step.
Reported result
Mean viable colony count: 18 colonies/25 cm² after manual cleaning, dropping to 0 colonies/25 cm² after treatment with the vapour system. The unit's MRSA incidence rate fell to zero after the intervention, with no new cases detected over 10 months of follow-up (as of the poster date).
Organisms / scope
MRSA — a real clinical setting (in-patient unit), not a controlled laboratory assay.
Limitations
A single-outbreak, single-unit case series with no parallel control group — not a controlled or randomized clinical trial. Conference poster material, not a peer-reviewed article in an indexed journal. Medizone International Inc. provided services and equipment at no cost for the study (conflict of interest disclosed on the poster itself).
Full reference
Zoutman D, Shannon M, de la Roche M, Chesterton D, Brown K. "Positive impacts of a new ozone and hydrogen peroxide vapour system to disinfect patient rooms during an MRSA outbreak." Poster presented at the IPAC Canada national conference, 2014.
Efficacy validation studies under an EPA-accepted (FIFRA) testing protocol — AsepticSure Disinfection Efficacy
EPA Validation 2015–2016 — Innovation Park / Queen's University · 2016
Authorship
Innovation Park (Queen's University), Kingston, ON — sponsored by Medizone International, Inc.
Relationship to the technology
Direct evidence from the Sterozone/AsepticSure platform
Nature of evidence
Regulatory (GLP) study under an EPA-accepted protocol
Access
Internal regulatory document — unpublished.
What this record supports
Validation of microbial-reduction efficacy under a testing protocol formally accepted by the US EPA (FIFRA), across multiple runs and different hydrogen-peroxide lots.
Method / conditions
Two studies conducted at Innovation Park/Queen's University (Kingston, ON) under an EPA-accepted testing protocol (FIFRA; Pre-Application No. 90607PA2; MRID 49533701), following EPA Guideline 810.2200 and AOAC method 961.02 (Germicidal Spray Products as Disinfectants Test — enclosed-room fogging application). Stainless-steel discs inoculated with S. aureus ATCC 6538 and P. aeruginosa ATCC 15442/14495 (+5% fetal bovine serum), placed at 20 positions per room (60 discs per organism per run), were exposed to 80 ppm ozone + 1.4% hydrogen peroxide (nominal) for 40 minutes at 21°C. 2015 study (December 2014–February 2015): 1 run, report MZEI-022315-090607. 2016 study (completed May 23, 2016): 3 runs with 3 different peroxide lots on different days — Laboratory Project ID MZEI-040316-09067 — totaling 180 discs tested per organism.
Reported result
In every run, the system met the EPA efficacy criterion of a minimum 5-log₁₀ reduction (1.0 × 10⁵) for S. aureus and P. aeruginosa. In the 2016 study (180 discs per organism, 3 lots): P. aeruginosa had 180 of 180 discs negative for the target organism (100%); S. aureus had 179 of 180 discs negative for the target organism (99.4%) — the single positive result (run 2) was identified by Vitek analysis as S. aureus itself. In the 2015 study (60 discs per organism, 1 run), the few growths observed were identified as laboratory contaminants (Cronobacter sakazakii; Gram-positive Bacillus), not the assay's target organisms.
Organisms / scope
S. aureus ATCC 6538 and P. aeruginosa ATCC 14495/15442 — enclosed-room fogging assay under EPA/AOAC regulatory protocol.
Limitations
A bench-scale study under a regulatory protocol (Good Laboratory Practice, 40 CFR Part 160), not a clinical outcome. '90607PA2' is an EPA pre-application number for an accepted testing protocol, not a granted product registration — an important distinction that should not be read as final product approval. Studies sponsored by Medizone International, Inc. The source documents carry FIFRA's standard confidentiality clause (the report is the sponsor's property, with use restricted to regulatory compliance); for that reason, the full file is not made available on this site — only on request.
Full reference
Medizone International, Inc. "AsepticSure Disinfection Efficacy" — Study Report MZEI-022315-090607 (Innovation Park/Queen's University, Kingston, ON; study completed Feb 26, 2015, report dated May 13, 2015); and Efficacy Validation Study, Laboratory Project ID MZEI-040316-09067 (study completed May 23, 2016). EPA Guideline 810.2200 / AOAC 961.02. EPA Pre-Application No. 90607PA2, MRID 49533701.
Effectiveness of a novel ozone and hydrogen peroxide gas-vapour system for the rapid high-level disinfection of surfaces and healthcare spaces
BMC Proceedings / ICPIC 2011 — Zoutman, Shannon & Brown · 2011
Authorship
Zoutman D, Shannon M, Brown K.
Relationship to the technology
Direct evidence from the Sterozone/AsepticSure platform
Nature of evidence
Peer-reviewed journal (open access)
Access
Open-access publication.
What this record supports
Independent, peer-reviewed confirmation of ultra-rapid chamber disinfection and its scale-up to a real room.
Method / conditions
Test chamber: 80 ppm ozone + 1% vaporized hydrogen peroxide, 80% relative humidity. Scaled up to an 82 m³ room using 3.75% hydrogen peroxide for 30 minutes. Organisms: MRSA, VRE, E. coli, P. aeruginosa and C. difficile spores, on stainless-steel discs.
Reported result
≥6 log₁₀ reduction of the bacteria and C. difficile spores tested, in just 15 minutes of exposure in the chamber; the same level of disinfection was replicated in an 81 m³ room in 30 minutes, using 3.75% hydrogen peroxide + 80 ppm ozone.
Organisms / scope
MRSA, VRE, E. coli, P. aeruginosa, C. difficile spores — test chamber and an 81–82 m³ room.
Limitations
A conference-proceedings abstract (ICPIC 2011, Geneva), peer-reviewed and published open access — not a full journal article and not a clinical outcome. Research funded by Medizone International Inc.; two of the three authors are employees and/or shareholders of the company (conflict of interest disclosed in the document itself).
Full reference
Zoutman D, Shannon M, Brown K. "Effectiveness of a novel ozone and hydrogen peroxide gas-vapour system for the rapid high-level disinfection of surfaces and healthcare spaces." BMC Proceedings. 2011;5(Suppl 6):O38.
Electrical safety certification of the Sterozone/AsepticSure equipment
QPS Evaluation Services — Certificate LR1402-1 (2017) · 2017
Authorship
QPS Evaluation Services Inc. (Toronto, ON — testing, certification and field evaluation body, accredited in Canada, the USA and internationally)
Relationship to the technology
Direct evidence from the Sterozone/AsepticSure platform
Nature of evidence
Independent third-party certification (equipment safety)
Access
Private manufacturer certification document.
What this record supports
Electrical and mechanical compliance of the equipment (hardware) with recognized safety standards — not a microbiological efficacy test.
Method / conditions
Electrical and mechanical safety testing under CAN/CSA-C22.2 No. 61010-1-12 and UL 61010-1 (3rd edition), on a representative sample of the AsepticSure Room Disinfection System (models MZEI2016-120-20A and MZEI2016-120-15A): protective conductor, earthing/bonding, dielectric voltage withstand, humidity conditioning, capacitor discharge, stability (tip-over, castors and support feet), static rigidity, impact, temperature, resistance to heat of the non-metallic enclosure, and cleaning.
Reported result
Compliance confirmed on every applicable test under the standards listed. Certificate of Compliance issued (ISO Type 3 certification system) — Report No. LR1402-1 (June 13, 2017; certificate signed June 29, 2017), QPS File No. LR1402.
Organisms / scope
Equipment electrical and mechanical safety — does not evaluate organisms or disinfection performance.
Limitations
This is an equipment (hardware) safety certificate, not a microbiological efficacy study, and should not be read as evidence of disinfection performance. QPS itself states it has not investigated the physiological effects of ozone. The authorization to reproduce the full report, as stated in the document itself, is granted to the applicant named on the Certificate of Compliance (Medizone International, Inc.); for that reason, the full file is not made available on this site — only on request.
Full reference
QPS Evaluation Services Inc. Certificate of Compliance / Certification Record — AsepticSure Room Disinfection System, models MZEI2016-120-20A and MZEI2016-120-15A. File No. LR1402, Report No. LR1402-1. Toronto, ON, Canada, 2017.
Block 2

Independent literature on terminal disinfection and environmental contamination

Important: the studies in this block do not test Sterozone/AsepticSure. They are included only to show that the concept — enhanced, no-touch terminal disinfection added to standard cleaning — is supported by high-quality independent evidence, including a randomized controlled trial. They must never be presented as proof of Sterozone's own performance.

Enhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the BETR-D study)
Anderson et al., Lancet 2017 (BETR-D) · 2017
Authorship
Anderson DJ, Chen LF, Weber DJ, et al.
Relationship to the technology
Independent context and comparator literature — does not test Sterozone/AsepticSure
Nature of evidence
Randomized controlled trial (independent literature)
Access
Subscription-access publication (journal).
What this record supports
Independent proof of concept: adding enhanced, no-touch terminal disinfection to standard cleaning reduces acquisition of target multidrug-resistant organisms.
Method / conditions
Pragmatic, multicentre, cluster-randomised crossover trial across 9 US hospitals, funded by the CDC. Compared standard terminal cleaning with the addition of no-touch UV-C disinfection in high-risk rooms.
Reported result
Adding no-touch UV-C to standard terminal disinfection of high-risk rooms reduced acquisition of the combined target multidrug-resistant organisms among exposed patients (statistically significant for the combined target organisms).
Organisms / scope
Target multidrug-resistant organisms (including MRSA, VRE, resistant Acinetobacter and ESBL-producing Enterobacteriaceae) and C. difficile — 9 US hospitals.
Limitations
IMPORTANT: this study does not test Sterozone/AsepticSure or any ozone-based technology — it evaluates enhanced, no-touch UV-C terminal disinfection. It is included only as independent evidence that the general concept (enhanced, no-touch terminal disinfection added to standard cleaning) reduces acquisition of multidrug-resistant pathogens. It must never be presented as proof of Sterozone's own performance.
Full reference
Anderson DJ, Chen LF, Weber DJ, et al. "Enhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal Room Disinfection study): a cluster-randomised, multicentre, crossover study." Lancet. 2017;389(10071):805-814.
Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile (BETR Disinfection secondary analysis)
Anderson et al., Lancet Infect Dis 2018 (BETR-D secondary analysis) · 2018
Authorship
Anderson DJ, Moehring RW, Weber DJ, et al.
Relationship to the technology
Independent context and comparator literature — does not test Sterozone/AsepticSure
Nature of evidence
Secondary analysis of a clinical trial (independent literature)
Access
Subscription-access publication (journal).
What this record supports
Hospital-wide effect: enhanced terminal disinfection in a targeted subset of high-risk rooms reduced hospital-wide incidence of C. difficile and VRE.
Method / conditions
Secondary analysis of the BETR-D trial (see previous record), examining the effect of enhanced terminal disinfection targeted at high-risk rooms on hospital-wide incidence rates, not only among directly exposed patients.
Reported result
Enhanced terminal disinfection with UV, applied to a targeted subset of high-risk rooms, led to a reduction in hospital-wide incidence of C. difficile and VRE.
Organisms / scope
C. difficile and VRE — hospital-wide incidence, 9 US institutions.
Limitations
IMPORTANT: like the original BETR-D trial, this analysis does not test Sterozone/AsepticSure — it evaluates no-touch UV-C terminal disinfection. It is included only as independent evidence for the general concept of enhanced terminal disinfection. It must never be presented as proof of Sterozone's own performance.
Full reference
Anderson DJ, Moehring RW, Weber DJ, et al. "Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile (BETR Disinfection secondary analysis)." Lancet Infect Dis. 2018;18(8):845-853.
Importance of the environment in meticillin-resistant Staphylococcus aureus acquisition: the case for hospital cleaning
Dancer, Lancet Infect Dis 2008 · 2008
Authorship
Dancer SJ.
Relationship to the technology
Independent context and comparator literature — does not test Sterozone/AsepticSure
Nature of evidence
Review article (independent literature)
Access
Subscription-access publication (journal).
What this record supports
Foundational rationale: contaminated surfaces are a source of MRSA transmission and standard cleaning is often insufficient — the premise the Sterozone proposal addresses.
Method / conditions
Review and argument on the role of the hospital environment in MRSA transmission and the limitations of standard hospital cleaning practices.
Reported result
Brings together evidence that contaminated environmental surfaces contribute to MRSA transmission in healthcare settings, and that conventional cleaning methods are not always sufficient to control that contamination.
Organisms / scope
MRSA — literature review on hospital environmental contamination.
Limitations
IMPORTANT: this article does not test Sterozone/AsepticSure or any specific disinfection technology — it is a review/rationale article. It is included only to show that the premise underlying the Sterozone proposal (residual environmental contamination after standard cleaning) is supported by independent literature. It must never be presented as proof of Sterozone's own performance.
Full reference
Dancer SJ. "Importance of the environment in meticillin-resistant Staphylococcus aureus acquisition: the case for hospital cleaning." Lancet Infect Dis. 2008;8(2):101-113.
How long do nosocomial pathogens persist on inanimate surfaces? A systematic review
Kramer, Schwebke & Kampf, BMC Infect Dis 2006 · 2006
Authorship
Kramer A, Schwebke I, Kampf G.
Relationship to the technology
Independent context and comparator literature — does not test Sterozone/AsepticSure
Nature of evidence
Systematic review (independent literature, open access)
Access
Open-access publication.
What this record supports
Foundational rationale: nosocomial pathogens survive on surfaces for days to months — reinforcing the premise the Sterozone proposal addresses.
Method / conditions
Systematic literature review on the survival time of healthcare-associated pathogens on inanimate surfaces.
Reported result
Documents that important nosocomial pathogens can survive on inanimate surfaces for periods ranging from days to months, depending on the organism and environmental conditions.
Organisms / scope
Multiple nosocomial pathogens — systematic literature review, no single organism.
Limitations
IMPORTANT: this article does not test Sterozone/AsepticSure or any specific disinfection technology — it is a systematic literature review. It is included only to show, with independent evidence, that environmental pathogen persistence is a real problem underlying the proposal. It must never be presented as proof of Sterozone's own performance.
Full reference
Kramer A, Schwebke I, Kampf G. "How long do nosocomial pathogens persist on inanimate surfaces? A systematic review." BMC Infect Dis. 2006;6:130.
Talk to the technical team

Need to assess the application for your environment?

The corresponding technical parameters and documentation accompany every commercial proposal. If you want to assess how this evidence applies to your operation, the next step is a conversation about your environment's characteristics.

Talk to the technical team